Ischemia-reperfusion injury: Beneficial effects of mesenchymal stromal cells

Current Opinion in Organ Transplantation

Volumn 18, Issue 1, 2013, Pages 34-43

  Souidi, Naima ^a   Stolk, Meaghan ^a   Seifert, Martina ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

cell therapy; inflammation; ischemia; mesenchymal stromal cells; reperfusion

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; INTERLEUKIN 10; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1;

ADAPTIVE IMMUNITY; CAUSE OF DEATH; CELL PROLIFERATION; CELL THERAPY; CELLS; CLINICAL TRIAL (TOPIC); COLD ISCHEMIA; DENDRITIC CELL; DNA DAMAGE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; INNATE IMMUNITY; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LUNG EDEMA; LUNG TRANSPLANTATION; MACROPHAGE; MESENCHYMAL STROMA CELL; METABOLIC DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; THROMBOCYTE AGGREGATION;

ACUTE DISEASE; ACUTE KIDNEY INJURY; ACUTE LUNG INJURY; ANIMALS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; HEART INJURIES; HUMANS; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MODELS, ANIMAL; PRIMARY GRAFT DYSFUNCTION; REPERFUSION INJURY; TRANSPLANTATION CONDITIONING;

EID: 84872924505     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835c2a05     Document Type: Review

References (107)

1. Eckle T, Kohler D, Lehmann R, et al. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 2008; 118:166-175.
2. Bernard A, Meier C, Ward M, et al. Packed red blood cells suppress T-cell proliferation through a process involving cell-cell contact. J Trauma 2010; 69:320-329.
3. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011; 305:1863-1872.
4. Siriussawakul A, Chen LI, Lang JD. Medical gases: a novel strategy for attenuating ischemia-reperfusion injury in organ transplantation? J Transplant 2012; 2012:819382.
5. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology 2009; 111:904-915.
6. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 2011; 17:1391-1401.
7. Qian L, Van Laake LW, Huang Y, et al. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011; 208: 549-560.
8. Kanzler H, Barrat FJ, Hessel EM, et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13:552-559.
9. Diepenhorst GM, van Gulik TM, Hack CE. Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg 2009; 249:889-899.
10. Liesz A, Suri-Payer E, Veltkamp C, et al. Regulatory T cells are key cere-broprotective immunomodulators in acute experimental stroke. Nat Med 2009; 15:192-199.
11. Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant 2011; 11:2279-2296.
12. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011; 6:457-478.
13. Togel FE, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6:179-183.
14. Morigi M, Rota C, Montemurro T, et al. Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 2010; 28:513-522.
15. Donizetti-Oliveira C, Semedo P, Burgos-Silva MT, et al. Adipose tissue-derived stem cell treatment prevents renal disease progression. Cell Transplant 2012; 21:1727-1741.
16. Hara Y, Stolk M, Ringe J, et al. In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transpl Int 2011; 24:1112-1123.
17. Kanazawa H, Fujimoto Y, Teratani T, et al. Bone marrow-derived mesench-ymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One 2011; 6:e19195.
18. Sun CK, Chang CL, Lin YC, et al. Systemic administration of autologous adipose-derived mesenchymal stem cells alleviates hepatic ischemia-re-perfusion injury in rats. Crit Care Med 2012; 40:1279-1290.
19. Chen S, Chen L, Wu X, et al. Ischemia postconditioning and mesenchymal stem cells engraftment synergistically attenuate ischemia reperfusion-in-duced lung injury in rats. J Surg Res 2012; 178:81-91.
20. Fang J, Chen L, Fan L, et al. Enhanced therapeutic effects of mesenchymal stem cells on myocardial infarction by ischemic postconditioning through paracrine mechanisms in rats. J Mol Cell Cardiol 2011; 51:839-847.
21. Yandza T, Tauc M, Saint-Paul MC, et al. The pig as a preclinical model for intestinal ischemia-reperfusion and transplantation studies. J Surg Res 2012 [Epub ahead of print]. doi:10.1016/j.ss.2012.07.025
22. Zhai Y, Busuttil RW, Kupiec-Weglinski JW. Liver ischemia and reperfusion injury: new insights into mechanisms of innate-adaptive immune-mediated tissue inflammation. Am J Transplant 2011; 11:1563-1569.
23. Frank A, Bonney M, Bonney S, et al. Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc Anesth 2012; 16:123-132.
24. Rock KL, Latz E, Ontiveros F, et al. The sterile inflammatory response. Annu Rev Immunol 2010; 28:321-342.
25. Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-797.
26. Atkinson C, He S, Morris K, et al. Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol 2010; 185:7007-7013.
27. McKay DB. The role of innate immunity in donor organ procurement. Semin Immunopathol 2011; 33:169-184.
28. Leventhal JS, Schroppel B. Toll-like receptors in transplantation: sensing and reacting to injury. Kidney Int 2012; 81:826-832.
29. De Vries DK, Schaapherder AF, Reinders ME. Mesenchymal stromal cells in renal ischemia/reperfusion injury. Front Immunol 2012; 3:162.
30. Satpute SR, Park JM, Jang HR, et al. The role for T cell repertoire/antigen-specific interactions in experimental kidney ischemia reperfusion injury. J Immunol 2009; 183:984-992.
31. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16:809-813.
32. Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008; 14:325-330.
33. Weissmuller T, Campbell EL, Rosenberger P, et al. PMNs facilitate translo-cation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest 2008; 118:3682-3692.
34. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proin-flammatory and procoagulant mediators in vivo. Cell 2009; 139:1143-1156.
35. Lisman T, Porte RJ. The role of platelets in liver inflammation and regeneration. Semin Thromb Hemost 2010; 36:170-174.
36. Den Hengst WA, Gielis JF, Lin JY, et al. Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol 2010; 299:H1283-H1299.
37. Martins PN, Chandraker A, Tullius SG. Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. Transpl Int 2006; 19:351-359.
38. Kotsch K, Martins PN, Klemz R, et al. Heme oxygenase-1 ameliorates ischemia/reperfusion injury by targeting dendritic cell maturation and migration. Antioxid Redox Signal 2007; 9:2049-2063.
39. Bidmon B, Kratochwill K, Rusai K, et al. Increased immunogenicity is an integral part of the heat shock response following renal ischemia. Cell Stress Chaperones 2012; 17:385-397.
40. Terasaki PI, Cecka JM, Gjertson DW, et al. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333:333-336.
41. Damman J, Daha MR, van Son WJ, et al. Crosstalk between complement and Toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant 2011; 11:660-669.
42. Perico N, Cattaneo D, Sayegh MH, et al. Delayed graft function in kidney transplantation. Lancet 2004; 364:1814-1827.
43. Yarlagadda SG, Coca SG, Formica RN Jr, et al. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24:1039-1047.
44. Zheng Q, Liu S, Song Z. Mechanism of arterial remodeling in chronic allograft vasculopathy. Front Med 2011; 5:248-253.
45. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378:1428-1437.
46. Leithead JA, Tariciotti L, Gunson B, et al. Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury. Am J Transplant 2012; 12:965-975.
47. Van der Kaaij NP, Kluin J, Haitsma JJ, et al. Surfactant pretreatment decreases long-term damage after ischemia-reperfusion injury of the lung. Eur J Cardiothorac Surg 2009; 35:304-312.
48. Burst VR, Gillis M, Putsch F, et al. Poor cell survival limits the beneficial impact of mesenchymal stem cell transplantation on acute kidney injury. Nephron Exp Nephrol 2010; 114:e107-e116.
49. Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289:F31-F42.
50. Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007; 72:430-441.
51. Liu H, Liu S, Li Y, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 2012; 7:e34608.
52. Togel FE, Westenfelder C. Kidney protection and regeneration following acute injury: progress through stem cell therapy. Am J Kidney Dis 2012 [Epub ahead of print]. doi: 10.1053/j.ajkd.2012.08.034
53. Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3:297.
54. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010; 16:203-209.
55. Teo GS, Ankrum JA, Martinelli R, et al. Mesenchymal stem cells transmigrate between and directly through TNF-alpha-activated endothelial cells. Stem Cells 2012; 30:2472-2486.
56. Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006; 27:1114-1122.
57. Togel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007; 292:F1626-F1635.
58. Assis AC, Carvalho JL, Jacoby BA, et al. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant 2010; 19:219-230.
59. Togel F, Zhang P, Hu Z, et al. VEGF is a mediator of the renoprotective effects of multipotent marrow stromal cells in acute kidney injury. J Cell Mol Med 2009; 13:2109-2114.
60. Lee JW, Gupta N, Serikov V, et al. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Ther 2009; 9:1259-1270.
61. Birukova AA, Zagranichnaya T, Fu P, et al. Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA-and Epac1/Rap1-depen-dent Rac activation. Exp Cell Res 2007; 313:2504-2520.
62. Fang X, Neyrinck AP, Matthay MA, et al. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem 2010; 285:26211-26222.
63. Poynter JA, Herrmann JL, Manukyan MC, et al. Intracoronary mesenchymal stem cells promote postischemic myocardial functional recovery, decrease inflammation, and reduce apoptosis via a signal transducer and activator of transcription 3 mechanism. J Am Coll Surg 2011; 213:253-260.
64. Sato T, Iso Y, Uyama T, et al. Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization. Lab Invest 2011; 91:553-564.
65. Jarvinen L, Badri L, Wettlaufer S, et al. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol 2008; 181:4389-4396.
66. Imberti B, Morigi M, Tomasoni S, et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol 2007; 18: 2921-2928.
67. Roemeling-van Rhijn M, Weimar W, Hoogduijn MJ. Mesenchymal stem cells: application for solid-organ transplantation. Curr Opin Organ Transplant 2012; 17:55-62.
68. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesench-ymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181:3933-3946.
69. Ge W, Jiang J, Baroja ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9:1760-1772.
70. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009; 37:1445-1453.
71. Maggini J, Mirkin G, Bognanni I, et al. Mouse bone marrow-derived me-senchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010; 5:e9252.
72. Wise AF, Ricardo SD. Mesenchymal stem cells in kidney inflammation and repair. Nephrology (Carlton) 2012; 17:1-10.
73. Collino F, Deregibus MC, Bruno S, et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 2010; 5:e11803.
74. Bruno S, Grange C, Collino F, et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One 2012; 7:e33115.
75. Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012; 18:759-765.
76. Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009; 20:1053-1067.
77. Cao H, Qian H, Xu W, et al. Mesenchymal stem cells derived from human umbilical cord ameliorate ischemia/reperfusion-induced acute renal failure in rats. Biotechnol Lett 2010; 32:725-732.
78. Brunswig-Spickenheier B, Boche J, Westenfelder C, et al. Limited immune-modulating activity of porcine mesenchymal stromal cells abolishes their protective efficacy in acute kidney injury. Stem Cells Dev 2010; 19:719-729.
79. Chen YT, Sun CK, Lin YC, et al. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med 2011; 9:51.
80. Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-in-duced acute and chronic kidney injury. Nephrol Dial Transplant 2011; 26:1474-1483.
81. La Manna G, Bianchi F, Cappuccilli M, et al. Mesenchymal stem cells in renal function recovery after acute kidney injury: use of a differentiating agent in a rat model. Cell Transplant 2011; 20:1193-1208.
82. Furuichi K, Shintani H, Sakai Y, et al. Effects of adipose-derived mesenchymal cells on ischemia-reperfusion injury in kidney. Clin Exp Nephrol 2012; 16:679-689.
83. Zhen-Qiang F, Bing-Wei Y, Yong-Liang L, et al. Localized expression of human BMP-7 by BM-MSCs enhances renal repair in an in vivo model of ischemia-reperfusion injury. Genes Cells 2012; 17:53-64.
84. Tian H, Lu Y, Shah SP, et al. 14S, 21R-dihydroxy-docosahexaenoic acid treatment enhances mesenchymal stem cell amelioration of renal ischemia/reperfusion injury. Stem Cells Dev 2012; 21:1187-1199.
85. Altun B, Yilmaz R, Aki T, et al. Use of mesenchymal stem cells and darbepoetin improve ischemia-induced acute kidney injury outcomes. Am J Nephrol 2012; 35:531-539.
86. Seifert M, Stolk M, Polenz D, et al. Detrimental effects of rat mesenchymal stromal cell pretreatment in a model of acute kidney rejection. Front Immunol 2012; 3:202.
87. Franquesa M, Herrero E, Torras J, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 2012; 21:3125-3135.
88. Alfarano C, Roubeix C, Chaaya R, et al. Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats. Cell Transplant 2012. doi: 10.3727/096368912X640448.
89. Herrmann JL, Wang Y, Abarbanell AM, et al. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock 2010; 33:24-30.
90. Kelly ML, Wang M, Crisostomo PR, et al. TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia. Shock 2010; 33:602-607.
91. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010; 4:214-222.
92. Li H, Zuo S, Pasha Z, et al. GATA-4 promotes myocardial transdifferentiation of mesenchymal stromal cells via up-regulating IGFBP-4. Cytotherapy 2011; 13:1057-1065.
93. Kim YS, Ahn Y, Kwon JS, et al. Priming of mesenchymal stem cells with oxytocin enhances the cardiac repair in ischemia/reperfusion injury. Cells Tissues Organs 2012; 195:428-442.
94. Zuo S, Jones WK, Li H, et al. Paracrine effect of Wnt11-overexpressing mesenchymal stem cells on ischemic injury. Stem Cells Dev 2012; 21: 598-608.
95. Song L, Xu J, Qu J, et al. A therapeutic role for mesenchymal stem cells in acute lung injury independent of hypoxia-induced mitogenic factor. J Cell Mol Med 2012; 16:376-385.
96. Chen Y, Qian H, Zhu W, et al. Hepatocyte growth factor modification promotes the amelioration effects of human umbilical cord mesenchymal stem cells on rat acute kidney injury. Stem Cells Dev 2011; 20:103-113.
97. Noiseux N, Gnecchi M, Lopez-Ilasaca M, et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006; 14:840-850.
98. Gnecchi M, He H, Melo LG, et al. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 2009; 27:971-979.
99. Xu J, Woods CR, Mora AL, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007; 293:L131-L141.
100. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179:1855-1863.
101. Li J, Li D, Liu X, et al. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm (Lond) 2012; 9:33.
102. Matthay MA, Thompson BT, Read EJ, et al. Therapeutic potential of me-senchymal stem cells for severe acute lung injury. Chest 2010; 138: 965-972.
103. Manning E, Pham S, Li S, et al. Interleukin-10 delivery via mesenchymal stem cells: a novel gene therapy approach to prevent lung ischemia-reperfusion injury. Hum Gene Ther 2010; 21:713-727.
104. Timmers L, Lim SK, Hoefer IE, et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011; 6:206-214.
105. Nguyen BK, Maltais S, Perrault LP, et al. Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J Cardiovasc Transl Res 2010; 3:547-558.
106. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307:1169-1177.
107. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54:2277-2286.